Who Optimizes SG&A Costs Better? Verona Pharma plc or Supernus Pharmaceuticals, Inc.

SG&A Cost Optimization: Supernus vs. Verona

__timestampSupernus Pharmaceuticals, Inc.Verona Pharma plc
Wednesday, January 1, 2014724710001802274
Thursday, January 1, 2015892040002512761
Friday, January 1, 20161060100002894488
Sunday, January 1, 20171379050008096274
Monday, January 1, 20181598880007985229
Tuesday, January 1, 20191584250008994597
Wednesday, January 1, 202020067700029772000
Friday, January 1, 202130475900033907000
Saturday, January 1, 202237722100026579000
Sunday, January 1, 202333636100049868547
Loading chart...

Cracking the code

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Supernus Pharmaceuticals, Inc. and Verona Pharma plc have taken different paths in optimizing these costs. From 2014 to 2023, Supernus Pharmaceuticals saw a staggering 364% increase in SG&A expenses, peaking in 2022. In contrast, Verona Pharma's expenses grew by approximately 2,667%, albeit from a much smaller base, reflecting its aggressive expansion strategy.

Supernus Pharmaceuticals, with its consistent growth, highlights a stable yet costly approach, while Verona Pharma's rapid increase suggests a focus on scaling operations. As the industry evolves, these strategies will play a pivotal role in determining market leadership. Investors and stakeholders should closely monitor these trends to gauge future performance and strategic direction.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025